Foreign in-house counsel face layered regulatory and title risks when acquiring a Kazakhstan pharma target. Here is what to check first. Make an enquiry.
Unlike a straightforward share purchase in a familiar market, acquiring or partnering with a local pharmaceutical company in Kazakhstan requires in-house counsel to navigate a regulatory architecture that is simultaneously shaped by Kazakhstani national law, Eurasian Economic Union (EAEU) technical regulations, and a series of sector-specific licensing and market-authorisation frameworks that have no direct equivalent in most Western legal systems. For foreign companies pursuing inbound transactions in the Kazakhstan pharmaceuticals sector, the due diligence exercise is not simply a checklist of corporate documents and financial statements — it is a structured investigation into whether the target can legally continue operating the day after closing, and whether its regulatory standing is portable to a foreign-owned entity.
Before instructing Kazakhstan-qualified counsel to commence formal due diligence, in-house counsel should assemble, and require the target to produce, the following:
If any of these items cannot be provided promptly, that is itself a material diligence finding.
The first and most consequential step in legal due diligence on a Kazakhstan pharma target is verifying the target's regulatory and licensing standing. A pharmaceutical manufacturer or wholesale distributor in Kazakhstan operates under a licence issued by the CMPC, which falls under the Ministry of Healthcare. That licence is issued to a specific legal entity at a specific address. It is not automatically transferable on a change of ownership, and it does not survive a reorganisation that results in a new legal entity.
In practice, this means that even a clean share purchase — where the legal entity continues to exist and the shares simply change hands — should not be assumed to leave the licence unaffected. Counsel should confirm, by direct verification with the CMPC register, that the licence is current, that no suspension or restriction order is outstanding, and that there are no pending inspections or administrative proceedings that could affect its validity.
The EAEU dimension adds a further layer. Pharmaceutical products sold within the EAEU must hold either a national market authorisation issued by the Kazakhstani regulator, or a unified EAEU market authorisation issued under the EAEU Pharmacopoeia and the Union's common registration rules. Where the target holds EAEU-format registrations, counsel should confirm that the marketing authorisation holder is the target entity (not a related company or an affiliate), and that renewal timelines are not approaching within the first 12 to 24 months post-closing.
Note: A pharmaceutical licence that is found to be conditionally suspended — even if the target's management describes it as "temporarily restricted" — may constitute a material breach of representations and warranties if not disclosed. Failure to complete the required corrective measures before a licence renewal deadline can result in the non-renewal of the licence and, consequently, the inability to manufacture or distribute lawfully in Kazakhstan. Counsel should treat any unresolved CMPC correspondence as a red-flag item requiring escalation before signing.
Having confirmed that the target's regulatory position is sound, counsel should turn to corporate title and beneficial ownership. Kazakhstan uses a civil law framework for corporate law, and the principal vehicle for a pharmaceutical business is a limited liability partnership (tovarishchestvo s ogranichennoy otvetstvennostyu, or TOO) or a joint-stock company (aktsionernoye obshchestvo, or AO). For each form, counsel should trace the full ownership chain through the State Register of Legal Entities and, where nominee arrangements are disclosed or suspected, should require notarised declarations of beneficial ownership.
The key title risks in a Kazakhstan pharmaceuticals acquisition are threefold. First, pre-emption rights under the partnership agreement or the articles of association may not have been properly waived by all existing participants, rendering any prior share transfer voidable. Second, historical capital contributions may have been made in-kind — using pharmaceutical equipment, inventory, or intellectual property — and the valuation records for those contributions should be reviewed to identify any undervaluation that could be challenged by a minority participant or a creditor. Third, where the target is a subsidiary of a larger domestic group, the question of intra-group guarantees, pledges over the target's assets, and related-party transactions should be examined with particular care. Kazakhstan law imposes specific approval requirements for major and related-party transactions, and unapproved transactions may be challenged as void.
Internal links: company formation in Kazakhstan for entity-form comparison; IP protection in Kazakhstan for intellectual property title issues affecting the product portfolio.
The financial and tax review in a Kazakhstan pharmaceuticals due diligence follows the same structural logic as in other jurisdictions, but with features specific to the Kazakhstani tax system. Kazakhstan operates a corporate income tax at a standard rate, with a reduced rate available for certain categories of taxpayer. More relevant for pharmaceutical companies is VAT on pharmaceutical products: certain essential medicines and medical devices may benefit from a zero rate or exemption, but the classification of products — and therefore the applicable VAT treatment — can be challenged by the State Revenue Committee.
Counsel should obtain, and independently verify, the target's tax compliance status for the preceding three years. This means requesting a formal certificate of absence of tax arrears, but also reviewing whether the target has any ongoing or recently closed tax audits, any transfer-pricing queries from the State Revenue Committee, or any disputes with the customs authority relating to the valuation of imported active pharmaceutical ingredients (APIs) or finished-dosage forms. Kazakhstan is an EAEU member, and customs clearance for goods moving within the EAEU is subject to the Union's unified customs code as well as national implementing rules — a source of procedural complexity that can generate unexpected liability.
For foreign investors acquiring a controlling stake, the question of thin capitalisation rules and the deductibility of interest on shareholder loans should be assessed at the same time, since restructuring the target's debt post-closing can generate tax events that were not anticipated in the pricing model.
A pharmaceutical company's value frequently resides not in its balance sheet but in its portfolio of marketing authorisations, proprietary formulations, and distribution network. Counsel should therefore examine employment and key-person arrangements, intellectual property title, and distribution contracts with equal rigour.
On employment, in-house counsel should confirm that the target's key technical personnel — qualified persons responsible for quality control under Kazakhstani GMP rules, and the pharmacist-director required for licensed activities — are employed directly by the target, not seconded from an affiliate or engaged as contractors. The departure or unavailability of qualified persons after closing can trigger a licence condition breach that the CMPC may act on quickly.
On intellectual property, the target's product dossiers — the regulatory files submitted to the CMPC for market authorisation — constitute a form of regulatory property that does not automatically pass with the shares. Counsel should confirm that the marketing authorisation holder and the legal entity are identical, that any licences to use third-party trademarks or formulations are in writing, and that those licences are assignable or survive a change of control. A detailed review of the target's trademark registrations with the National Institute of Intellectual Property (NIIP) and any pending oppositions or cancellation actions is warranted. See the firm's overview of IP protection in Kazakhstan for further context.
On distribution, the target may hold exclusive distribution agreements that are critical to its revenue but terminable on change of control. These require careful drafting in representations and warranties, and may need to be renegotiated or novated as a condition to closing. In a sector where pricing and reimbursement status is determined by government tender and inclusion on the Essential Medicines List, the durability of the target's revenue stream post-acquisition should be stress-tested against tender renewal cycles.
The final step is an assessment of pending and threatened litigation, administrative proceedings, and any cross-border enforcement exposure. Kazakhstan has a three-tier state court system (district courts, regional courts, and the Supreme Court), a specialised administrative court jurisdiction for regulatory disputes, and an active arbitration infrastructure including the Kazakhstan International Arbitration Centre (KIAC) and the International Arbitration Centre at the AIFC (IAC AIFC) for parties operating under English law at the Astana International Financial Centre.
Counsel should obtain a litigation search certificate, confirm whether the target or its directors are respondents in any CMPC administrative proceedings, and review any outstanding state inspections. Where the target supplies to government-funded healthcare programmes — as many Kazakhstani pharmaceutical companies do — counsel should also review whether there are any outstanding claims arising from tender irregularities, short deliveries, or quality disputes with procurement authorities.
For foreign investors acquiring a Kazakhstan target as part of a wider regional strategy, the cross-border dimension matters. Intra-group contracts between a Kazakhstan entity and a Russian-law entity — supply agreements, service agreements, loans — create enforcement questions if the relationship deteriorates. The interaction between Kazakhstani civil procedure and Russian civil procedure for enforcement of foreign judgments and foreign arbitral awards is an area where early structuring choices — including governing law and dispute resolution clauses — can significantly affect the cost and speed of any eventual recovery. Our cross-border disputes practice page sets out the principal options for Kazakhstan–Russia transaction structuring from a disputes perspective.
Q: How long does legal due diligence on a Kazakhstan pharmaceutical target typically take?
A: The duration depends on the target's organisational complexity and the responsiveness of its management in providing documents. For a mid-sized pharmaceutical manufacturer or distributor in Kazakhstan, a full-scope legal due diligence exercise — covering regulatory, corporate, financial-legal, employment, IP, and litigation workstreams — typically requires between four and eight weeks from the date the data room is opened. Regulatory verification with the CMPC, in particular, can extend timelines if the regulator does not respond to official enquiries promptly. Foreign in-house counsel should build adequate time into the transaction timetable and avoid treating the due diligence period as fixed at the outset.
Q: What documents should a target provide at the outset of due diligence?
A: At minimum, a Kazakhstan pharmaceutical target should provide: the current state registration certificate and constitutional documents; all CMPC-issued licences with their conditions and validity dates; the three most recent years of audited financial statements; a current beneficial ownership disclosure; and a schedule of material contracts. GMP and GDP certificates, together with the most recent CMPC inspection report, should be requested at the same time. Counsel should treat any reluctance to produce the beneficial ownership disclosure or the inspection report as a potential indicator of undisclosed regulatory issues.
Q: What happens if the target's pharmaceutical licences are found to be non-compliant or subject to conditions?
A: A finding of non-compliance or conditional restriction on a CMPC-issued licence is a material issue that must be addressed before closing. In practice, the options are: requiring the target to remediate the non-compliance and obtain written CMPC confirmation before closing; structuring a price adjustment mechanism or escrow to account for the cost and risk of post-closing remediation; or, in serious cases, renegotiating the scope of the transaction or withdrawing. Where the licence condition relates to GMP infrastructure or quality systems, remediation can take six months or longer, and any assessment of the remediation cost should be prepared by a qualified GMP consultant, not solely by legal counsel.
This briefing is general information and does not constitute legal advice. For advice on a specific matter, write in confidence to info@vetrovpartners.com.
Our team advises foreign clients on exactly these questions across Russia and the EAEU region. Initial 30-minute consultation — complimentary.
Make an enquiry